MEDINCELL | BUY coverage initiated | EUR10 | Injecting more value
MedinCell has developed a proprietary technology called BEPO® which makes it possible to develop the formulation of molecules as long-acting injectables. This presents clear advantages for compounds in diseases where convenience and adherence to treatment matter the most. Therefore, it combines an attractive market opportunity with a fairly low risk of development.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.